Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs
FDF: Moved up the value chain in formulations
Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.
Bio: Recombinant products
Laurus Labs concall takeaways \U0001f9ec
— JST Investments (@JstInvestments) April 30, 2021
Targetting $1B revenues & much more afterward (Increased capex guidance for FY22-23 from 1000crs to 1700crs)#Q4withJST #Pharma pic.twitter.com/lFcjPCOhWl
LAURUSLABS
— Saket Reddy (@saketreddy) May 3, 2021
Haters are gonna hate, but IMO, this is the best opportunity to start pyramiding and make it a well sized holding.
A trio of patterns coming together, has one of the highest success rate!
Double Top Buy, T20 Pattern - Bullish & Super pattern - Bullish above 477.81! https://t.co/SqzkTyb9wx pic.twitter.com/hTj7mfAOqy
For three years I have wanted to write an article on moral panics. I have collected anecdotes and similarities between today\u2019s moral panic and those of the past - particularly the Satanic Panic of the 80s.
— Ashe Schow (@AsheSchow) September 29, 2018
This is my finished product: https://t.co/otcM1uuUDk
Sir, Log yahan.. 13 days patience nhi rakh sakte aur aap 2013 ki baat kar rahe ho. Even Aap Ready made portfolio banakar bhi de do to bhi wo 1 month me hi EXIT kar denge \U0001f602
— BhavinKhengarSuratGujarat (@IntradayWithBRK) September 19, 2021
Neuland 2700 se 1500 & Sequent 330 to 230 kya huwa.. 99% retailers/investors twitter par charcha n EXIT\U0001f602